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Abstract
Background: Multiple sclerosis (MS) is a chronic progressive condition affecting the central nervous system.
Progression of MS results in increased level of disability and most patients will eventually experience some degree
of functional impairment and impaired mobility. Costs and burdens escalate as MS disability increases. However,
there is a lack of recent data on the impact of MS disability on the cost and burden among patients in the US.
Methods: Data for this study were drawn from a real world, cross-sectional survey undertaken between 2013 and
2014. Neurologists completed detailed patient report forms (PRF) for the most recent consulting patients with MS
(age >18 years). Patient’s perceptions of their diagnosis and health-related quality of life (HRQoL) were collected
through a patient self-completion questionnaire (PSC). Regression analysis was used to evaluate the relationship
between disability (determined by latest Expanded Disability Status Scale [EDSS] score) and current relapse and
health care resource utilization, health care costs, HRQoL and work productivity.
Results: PRF data were collected for 715 patients (335 also completed a PSC). Patients with higher disability scores
(EDSS 3–5 and >5 vs <3 points) and current relapse (vs no current relapse) reported significantly greater health
resource utilization for physician visits (p < 0.05) and hospitalizations (p < 0.05) in the preceding 12 months. In
addition, they had poorer HRQoL (p < 0.05), were significantly more likely to be unemployed (p < 0.05) and to have
had to stop working due to MS (p < 0.05). They also incurred significantly higher health care related costs, including
costs for physician consultations, hospitalizations and therapy (p < 0.05). The total costs of care were $51,825,
$57,889 and $67,116 for EDSS < 3, EDSS 3–5 and EDSS > 5 groups, respectively; $51,692 and $58,648 for non-relapse
and relapse groups, respectively.
Conclusions: For MS patients in the US, health resource utilization and healthcare care costs increase with
progression of disability. As the disability worsens, patients also exhibit diminished HRQoL and lower work
productivity. There is a need for treatments that slow down or delay disability progression among MS patients.
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Background
Multiple sclerosis (MS) is a chronic progressive condi-
tion affecting the central nervous system and character-
ized by localized areas of inflammation, demyelination
and axonal degeneration [1]. This process results in a
wide range of neurological symptoms, most commonly
autonomic, visual, motor, and sensory in nature [1]. The
progression of the neurological symptoms of MS may be
ongoing (progressive MS) or associated with periodic
worsening or relapses (relapsing-remitting MS) [2]. In
the US, the number of MS patients has been estimated
to be between 400,000 and 570,000 [3].
Progression of the neurological symptoms of MS results
in increased level of disability and the majority of patients
will eventually experience some degree of functional im-
pairment and impaired mobility [4, 5]. In addition to
impacting a patient’s ability to self-care and living inde-
pendently [6], functional and mobility impairments can
have an impact on the ability to work. Indeed, disease pro-
gression and the associated increase in disability have been
associated with increased levels of unemployment [7, 8].
Symptoms of MS generally appear between the ages of 20
and 40 years, a time when individuals may be establishing
their careers, starting a family or having a number of de-
pendents to provide for [9]. The loss of independence and
ability to work and provide for themselves and their fam-
ilies can have profound detrimental effects on patient’s
health-related quality of life (HRQoL), social participation
and psychological health, in addition to a considerable
financial burden [10–13].
Several studies have suggested that costs and burdens
associated with MS escalate with increased disability and
may include the need for inpatient care in a skilled nurs-
ing facility for those most severely affected [14–17]. In
addition, patients with MS accrue a considerable per-
sonal financial burden associated with missed work days,
lost productivity and unemployment, as well as costs
attributable to coping with the functional and mobility
impairments including informal care costs, mobility aids,
transportation costs, and home modifications [3, 18]. A
limitation of the current evidence base regarding the
burden and costs of MS is that the majority of the stud-
ies described above were conducted using data pre-2010
and as such a re-evaluation of the cost and burden of
this chronic progressive condition is warranted. In par-
ticular, there is a need to examine the relationship
between disability and health-care resource utilization
(HCRU) and associated costs within the context of the
new treatment options available, including oral disease-
modifying drugs (DMDs), and the recognition that early
intervention has the potential to slow the progression of
the disease [19].
To address the lack of recent data on the disability as-
sociated with MS and its related impact on the burden
on patients in the US, we conducted a real world, cross-
sectional survey. The aim of the research was to quantify
the relationship between increased disability and HRCU,
healthcare cost, quality of life (QoL), ability to work and
productivity while at work among patients with MS.
Methods
Study design
Data were drawn from the Adelphi MS III Disease Spe-
cific Programme (DSP® [20]). The Adelphi MS III DSP
was a real-world, cross-sectional survey of neurologists
caring for patients with MS in the USA. Physicians spe-
cializing in the management of patients with MS were
identified using national databases, the internet, medical
literature, and local physician networks and societies. A
regional stratification approach was used to ensure geo-
graphical representativeness of the physician sample.
The survey, undertaken between 2013 and 2014, con-
sisted of a physician-reported patient record form (PRF)
and a patient self-completed questionnaire (PSC). The
study population consisted of 715 patients with a diag-
nosis of MS who were >18 years of age and had been
receiving treatment with any disease-modifying agent for
the previous 12 months. Data for these patients were ob-
tained from participating neurologists who completed a
detailed PRF for the most recent consulting patients
with a diagnosis of MS.
The research was conducted in full accordance with
the US Health Insurance Portability and Accountability
Act 1996 (HIPAA; www.hhs.gov/ocr/privacy/). All data
were collected via ethically approved procedures through
local fieldwork partners, including the informed consent
of patients, and data was fully de-identified prior to re-
ceipt by Adelphi. Full details of the DSP methodology
and of the methodology for the MS DSP have previously
been published [20, 21].
Physician-reported data
The PRF collected information from patient records on
patient demographics and disease characteristics including
time since diagnosis, symptoms at diagnosis, healthcare
resource utilization (medication use, hospitalizations,
emergency room [ER] visits, physician consultations, other
healthcare professional [HCP] consultations, and support-
ive therapies), and whether the patient was considered to
have experienced a recent relapse. Physicians were also
asked to provide an Expanded Disability Status Scale
(EDSS [22]) score where available. Only information avail-
able to the physician at the time of the patient consult-
ation was collected.
Patient-reported data
Patients for whom a PRF had been completed were
invited to complete a PSC independently. The PSC
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collected information about the patient’s perceptions of
their diagnosis, HRQoL (as assessed using the EQ-5D-
3L health states and visual analog scale (VAS) and the
Hamburg Quality of Life Questionnaire Multiple
Sclerosis [HAQUAMS; [23]). The EQ-5D-3L consists
of 5 health dimensions (mobility, self-care, usual ac-
tivities, pain/discomfort and anxiety/depression) and
each dimension is scored from no, some or extreme
problems. These responses are used to derive an
index score that ranges from −0.11 (worse than
death) to 1 (full health), with lower scores represent-
ing lower quality of life. For the EQ-5D-3L, the
country-specific value set for the USA was applied.
The HAQUAMS consists of 38 items that examine
general health perception and five health dimensions
relevant for patients with MS (fatigue/thinking, mobil-
ity lower limb, mobility upper limb, social function
and mood). A composite score is derived ranging
from 1 to 5 with higher scores indicating poorer per-
ceived HRQoL.
Patients were also asked to complete questions regard-
ing their employment status, the impact of their MS on
their ability to work and time lost to work as a result of
their MS. Information of the work-related burden of MS
was collected using the Work Productivity and Activity
Impairment Questionnaire (WPAI) which was included
as part of the PSC [24]. All answers were anonymised to
preserve confidentiality and the patient responses were
then matched to the corresponding PRF via patient and
physician study numbers. The matching of these forms
enabled analysis of corresponding data from the physi-
cian’s PRF.
Statistical analysis
Analysis was restricted to RRMS patients receiving a
DMD continuously for the previous 12 months.
The relationship between disability, as measured using
the EDSS, and current relapse and healthcare resource
utilization, healthcare costs, HRQoL, and work product-
ivity was evaluated using regression analysis. Patient age,
sex and body mass index were included as covariates in
all regression analyses. These covariates were selected as
being variables commonly regarded as potentially con-
founding or interacting with a variety of health states in-
cluding MS. The clinical course of MS is age-related and
older age tends to be associated with increased fragility
and increased severity of any other comorbid health
conditions. Gender has also been shown to impact the
clinical expression of MS as well as responses to therapy.
BMI may be indicative of current overall health. Regres-
sion analyses were chosen in order to strike a balance
between the need for strong modelling and interpretabil-
ity of the output data. The same approach was used for
all analyses in order to ease the interpretation of
coefficients. While using different models for some ana-
lyses may have provided a better fit to the model, it was
felt that this would have offered little advantage and ren-
dered interpretation more challenging.
The EDSS is a 10-point scale with 0.5 point incre-
ments reflecting increased levels of disability [22]. Scores
of 1 to 4.5 define patients able to walk, scores of 5 to 9.5
define patients with impaired walking. Impairment in
eight functional systems (pyramidal [limbs], cerebellar,
brainstem, sensory, bowel and bladder, visual, cerebral
and other) is reflected in increased EDSS scores. An
EDSS score of <3 was defined as the reference group for
comparison as these patients experience no, minimal or
mild disability. Comparator groups were patients with
EDSS score 3–5 who experience moderate to significant
disability with limited impairment of activities and
patients with EDSS scores >5 points who experience dis-
ability severe enough to impair daily activities and ability
to work a full day. Patients reported to have suffered a
relapse in the last 12 months were compared to the
reference group of those not having suffered a relapse in
the last 12 months, according to their physician.
Direct medical costs (health care practitioner consulta-
tions, hospitalizations, current treatment regimen) were
calculated as US$/year. Given the lack of nationally rep-
resentative healthcare costs for the US, unit costs were
derived from a number of sources. The unit cost per
hospital stay was based on the estimate reported by
O’Brien et al. [25] adjusted for inflation to 2015 dollars;
physician consultation costs were derived from the
Annual Physician Fee Schedule Payment 2015 database
[26] and medication costs were derived from the US
Department of Veterans Affairs National Acquisition
Center cost database [27]. Direct medical costs were
calculated based on healthcare resource utilization as
recorded in the PRFs for patients in all analysis cohorts.
Logistic regression was used for binary outcomes (pro-
ducing odds ratios [ORs]), negative binomial regression
for count outcomes (producing incidence rate ratios
[IRRs]), and ordinary least squares for all other outcome
types (producing coefficients). All regressions were ad-
justed for patient age, sex, and BMI. Standard errors
were adjusted for possible correlation within reporting
physician. All analyses were carried out using STATA
14.1 (StataCorp 2015. Stata Statistical Software: Release
14. College Station, TX: StataCorp LP).
Results
A total of 109 neurologists provided PRFs for 715
patients with MS. Of these 715 patients, 335 also com-
pleted a PSC. No relevant demographic differences were
noted between the cohort of patients providing a PSC and
those who did not (data on file). The baseline demo-
graphic characteristics of the study population are shown
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in Table 1. In all, 31 % of the patient cohort was male, the
mean age was 42.1 years and the mean time since diagno-
sis of MS was 6.9 years. Interferon beta-1a was the most
common current DMDs (32.2 %) followed by Glatiramer
acetate (24.9 %).
Association between MS disability and disease burden
Healthcare resource utilization
Compared to patients with an EDSS <3, those with
higher disability scores made significantly more visits to
a neurologist (EDSS 3–5, IRR 1.3; EDSS >5, IRR 1.4),
MS nurse (EDSS 3–5, IRR 6.6; EDSS >5, IRR 44.4), a
physiotherapist (EDSS 3–5, IRR 3.2; EDSS >5, IRR 9.9),
and a urologist (EDSS 3–5, IRR 4.8; EDSS >5, IRR 7.2)
in the previous 12 months (p < 0.05 for all comparisons;
Table 2). Those in the highest disability group had
significantly more hospitalizations in the previous
12 months (IRR 3.3, p < 0.05).
Relapsing was notably associated with increased
healthcare resource utilization (Table 2). Compared with
patients with no relapse, those with relapse made signifi-
cantly more visits to a neurologist, primary care physician,
ER doctor, ophthalmologist, gastroenterologist or psych-
iatrist and had more hospitalizations in the previous
12 months (p < 0.05 for all; Table 2).
HRQoL
Patients with higher disability scores and disease relapse
were more likely to perceive their MS as a major prob-
lem in their life that causes upset (p < 0.05 for EDSS 3–5
and EDSS >5 groups compared with EDSS <3 group;
Table 3). Patients with greater disability were more likely
to report poorer health status (EQ-5D) and poorer per-
ceived QoL (EQ-5D VAS) (p < 0.05 for EDSS 3–5 and
EDSS >5 groups compared with EDSS <3 group;
Table 3).
Using the MS-specific HRQoL tool HAQUAMS, in-
creased disease severity was associated with an increased
likelihood of worse HRQoL in terms of the overall score
and scores on all subscales (p < 0.05 for EDSS 3–5 and
EDSS >5 groups compared with EDSS <3 group).
Relapsing was associated with worse HRQoL measured
by either EQ-5D or HAQUMAS (Table 3). In general,
patients who experienced relapses had lower HRQoL
than patients with no relapses (p < 0.05 for all except for
EQ-VAS; Table 3).
Work and productivity
Compared to patients with an EDSS <3, those with a
higher disability score were significantly more likely to
be unemployed (EDSS of 3–5, OR 2.8; EDSS >5, OR
12.4; p < 0.05 for both comparisons) (Table 4). These pa-
tients were also significantly more likely to have been
unable to get a job or a promotion due to their MS
(EDSS 3–5 OR 4.8; EDSS >5 OR 17.0; p < 0.05 for both
comparisons) or had to stop work altogether (EDSS 3–5
OR 2.6; EDSS >5 OR 10.4; p < 0.05 for both compari-
sons) due to their MS. Patients in the EDSS 3–5 group
were significantly more likely to have experienced im-
pairment while working (+13.3 %) and overall work
impairment (+15.4 %) than those in the EDSS <3 group
(p < 0.05 for both comparisons). Activity impairment was
significantly greater for patients in both higher disability
groups compared with those in the EDSS <3 group
(EDSS 3–5, +16.8 %; EDSS >5, +33.6 %; p < 0.05 for both
comparisons) as measured using the WPAI (Table 4).
Compared with patients without relapse, those with
relapse were significantly more likely to have had to
reduce their weekly working hours due to their MS (OR
2.3; p < 0.05) (Table 4).
Table 1 Patient demographics and disease characteristics
Patient population
N = 715
Age, mean years (SD) 42.1 (10.7)







Employment status, N (%)
Employed 422 (59.0)
Housing status, N (%)
Lives alone 139 (19.4)
Lives with partner/spouse 463 (64.8)
Lives with other friends/family 108 (15.1)
Missing 5 (0.7)
Relationship status, N (%)
Single 112 (15.7)
In a relationship 476 (66.6)
Divorced/separated/widowed 111 (15.5)
Missing 16 (2.2)
Time since initial MS diagnosis, mean years(SD) 6.9 (5.3)a
Current DMDs, N (%)
Interferon beta-1a 230 (32.2)
Interferon beta-1b 66 (9.2)
Glatiramer acetate 178 (24.9)
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Economic costs associated with increased disability
Direct costs associated with health care practitioner
consultations, hospitalizations and medications in the
previous 12 months are shown in Table 5. As disabil-
ity progressed, the direct costs associated with phys-
ician visits, hospitalization and medications also
increased. The total costs of care were $51,825,
$57,889 and $67,116 for EDSS < 3, EDSS 3–5 and
EDSS > 5 groups, respectively. Relapse was also associ-
ated with increased costs. The total costs of care were
$51,692 and $58,648 for the non-relapse and relapse
groups, respectively.
Costs associated with health care practitioner consul-
tations significantly increased among patients with
Table 2 Relationship between disability (EDSS) and relapse and health care resource utilization among patients with MS
Parameter, (95 % CI) Disability (reference group EDSS <3; n = 411) Relapsed (n = 303)
(reference group
no relapse; n = 341)
R2, %b
EDSS 3–5 (n = 167) EDSS > 5 (n = 66)
Consultations in the last 12 monthsa
Neurology 1.3* (1.2–1.5) 1.4* (1.2–1.6) 1.2* (1.1–1.4) 4.42
Primary care physician 1.0 (0.6–1.5) 0.9 (0.5–1.5) 1.5* (1.1–2.0) 0.71
MS specialist 1.0 (0.4–2.7) 0.5 (0.1–1.9) 2.4 (0.8–7.3) 1.84
MS Nurse 6.6* (2.4–18.2) 44.4* (8.0–248.2) 0.8 (0.3–2.1) 7.28
Internist 1.3 (0.5–3.2) 0.4 (0.1–1.3) 1.6 (0.6–4.2) 1.97
Emergency room doctor 1.9 (0.6–5.7) 0.8 (0.2–3.6) 15.6* (2.2–109.9) 12.98
Physiotherapist 3.2* (1.0–10.1) 9.9* (3.2–30.7) 1.5 (0.5–4.4) 5.06
Ophthalmologist 1.6 (0.9–3.0) 2.3 (1.0–5.4) 4.3* (2.0–8.9) 8.68
Urologist 4.8* (1.9–12.0) 7.2* (2.2–23.6) 1.8 (0.8–3.9) 7.67
Gastroenterologist 4.4 (0.6–32.3) 9.7 (0.9–101.9) 7.0* (1.2–41.4) 11.24
Psychiatrist 1.5 (0.4–5.4) 1.5 (0.3–7.1) 2.8* (1.0–7.7) 2.90
Other physician 3.9 (0.9–17.6) 6.3 (1.0–40.6) 1.8 (0.7–4.2) 7.69
Hospitalizations in the last 12 monthsa 1.7 (0.8–3.3) 3.3* (1.6–6.8) 7.1* (3.3–15.5) 15.37
EDSS Expanded Disability Status Scale, MS multiple sclerosis
*p < 0.05
aNegative binomial analysis to yield IRRs and 95 % CIs (covariates: patient age, sex and body mass index)
bMcFadden’s R-Squared
Table 3 Relationship between disability (EDSS) and relapse and health-related quality of life among patients with MS
Parameter, (95 % CI) Disability (reference group EDSS <3; n = 201) Relapsed (n = 148)
(reference group
no relapse; n =
155)
R2, %
EDSS 3–5 (n = 78) EDSS >5 (n = 24)
MS is a major problem in life and causes upset a,b 1.6* (0.9–2.4) 3.1* (2.1–4.2) 1.0* (0.3–1.7) 26.79
EQ-5Db,c
Health State −0.09* (−0.13–-0.05) −0.25* (−0.33–-0.18) −0.05* (0.08–-0.01) 29.98
VAS −11.1* (−14.8– -7.3) −25.2* (−34.2– -16.2) −2.9 (−5.9–-0.1) 31.93
HAQUAMSb,d
Total score 0.5* (0.3–0.7) 1.1* (0.8–1.4) 0.2* (0.1–0.4) 39.95
Fatigue/thinking subscale 0.5* (0.2–0.7) 1.2* (0.8–1.6) 0.2 (−0.1–0.4) 27.51
Mobility/lower limb subscale 0.5* (0.3–0.7) 1.7* (1.3–2.1) 0.2* (0.1–0.4) 46.91
Mobility/upper limb subscale 0.5* (0.2–0.7) 1.3* (0.9–1.7) 0.3* (0.1–0.5) 36.45
Social function scale 0.3* (0.1–0.6) 0.4* (0.0–0.8) 0.2* (0.0–0.4) 11.99
Mood subscale 0.6* (0.4–0.9) 0.9* (0.6–1.3) 0.4* (0.2–0.6) 29.00
EDSS Expanded Disability Status Scale, HAQUAMS Hamburg Quality of Life Questionnaire Multiple Sclerosis, MS multiple sclerosis, VAS visual analog scale
*p < 0.05
aOrdinal scale of 1 to 10 (1 completely disagree to 10 completely agree)
bOrdinary least squares regression analysis to yield coefficients and 95 % CIs (covariates: patient age, sex and body mass index)
cLower score indicates worse HRQoL
dHigher score indicates worse HRQoL
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higher disability scores compared with those with the
lowest disability scores (EDSS 3–5, +$692; EDSS >5,
+$730; p < 0.05) (Table 6). Higher levels of disability
were associated with higher costs over the previous
12 months for hospitalizations (+$10,883; p < 0.05) and
total MS costs (consultations, hospitalizations and cost
of treatment) (+$13,324; p < 0.05; Table 6).
Relapsing was notably associated with increased health
care costs (Table 6). Compared with those with no re-
lapse, patients with relapse accrued significantly higher
costs over the previous 12 months for physician con-
sultations (+$464; p < 0.05), hospitalizations (+$3693;
p < 0.05) and total MS costs (+$4390; p < 0.05).
Discussion
This study has highlighted the considerable burden of
disability associated with MS on patients in the US using
the real-world survey data from MS patients and neurol-
ogists caring for these patients.
Although previous studies have demonstrated that MS
is associated with considerable rates of unemployment
[28, 29] and that absenteeism and presenteeism are com-
mon among patients with MS [30], large-scale evalua-
tions of the real-world association between MS and
employment and productivity in the workplace are lack-
ing. In 915 US-based patients with MS receiving treat-
ment in 2013, increased disability was associated with a
marked impact on the ability of patients to work, as
reflected by a greater likelihood of being unemployed, a
greater likelihood of having to reduce their working
hours or to have changed their job as a result of their
condition. In a cohort of 337 individuals with the
relapsing-remitting form of MS, 14 % of patients re-
ported having to take time away from work due to their
MS (absenteeism) and 47 % reported lost productivity at
work as a result of their MS (presenteeism) [30]. Re-
cently, several studies in small cohorts of patients with
MS have suggested that fatigue, cognitive function and
motor function may mediate the impact of disability on
Table 4 Relationship between disability (EDSS) and relapse and ability to work, productivity and employment status among patients
with MS
Parameter, (95 % CI) Disability (reference group EDSS <3; n = 201) Relapsed (n = 148)
(reference group no
relapse; n = 155)
R2, %c
EDSS 3–5 (n = 78) EDSS >5 (n = 24)
Unemployeda 2.8* (1.7–4.4) 12.4*(6.3–24.4) 1.1 (0.8–1.7) 15.20
Had to change job due to MSa 2.5 (0.7–8.5) 14.4* (4.5–46.0) 0.6 (0.2–1.7) 9.97
Had to reduce weekly working hours due to MSa 1.7 (0.8–3.5) 1.4 (0.4–4.6) 2.3* (1.3–4.1) 4.72
Unable to get a job or promotion due to MSa 4.8* (1.4–16.1) 17.0* (4.2–68.4) 1.7 (0.6–4.8) 17.51
Had to retire early due to MSa 1.1 (0.3–3.5) 2.2 (0.5–9.0) 1.9 (0.6–6.4) 13.22
Had to stop work altogether due to MSa 2.6* (1.1–6.3) 10.4* (3.5–30.8) 1.0 (0.4–2.1) 14.59
WPAIb
% work time missed 4.2 (−2.6–11.0) 1.8 (−8.0–11.5) 3.2 (−1.2–7.7) 4.75
% impairment while working 13.3* (5.5–21.0) 12.0 (−26.5–50.6) 13.4* (6.3–20.6) 22.59
% overall work impairment 15.4* (6.7–24.1) 21.0 (−35.7–77.7) 12.8* (5.2–20.4) 24.02
% activity impairment 16.8* (9.3–24.2) 33.6*(23.2–44.0) 9.9* (3.3–16.5) 31.00
EDSS Expanded Disability Status Scale, MS multiple sclerosis, WPAI Work Productivity and Activity Impairment Questionnaire
*p < 0.05
aLogistic regression analysis to yield ORs and 95 % Cis (covariates: patient age, sex and body mass index)
bOrdinary least squares regression analysis to yield coefficients and 95 % CIs (covariates: patient age, sex and body mass index)
cR-Squared for ordinary least squares regression, McFadden’s R-Squared for logistic regression





Physician visits Hospitalization costs Medication costs Total direct costs
EDSS <3 1,659 (898.3) 1,546 (7017.1) 48,620 (10,612.2) 51,825 (12,741.8)
EDSS 3–5 2,545 (1,627.0) 6,217 (14402.5) 49,127 (12,319.3) 57,889 (20,020.7)
EDSS >5 2,491 (1,181.1) 14,303 (27,380.7) 50,321 (11,288.1) 67,116 (31,605.9)
No relapse 1,612 (986.6) 1,480 (7,464.0) 48,600 (10,520.9) 51,692 (13,017.6)
Relapsed 2,381 (1,347.2) 6,974 (17,250.4) 49,294 (11,808.4) 58,648 (22,128.2)
EDSS Expanded Disability Status Scale, SD standard deviation
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work status [31–33]. Our results confirm and extend
these previous findings and highlight the relevance of
increased disability as a driver of decrements in the
capacity to work among patients with MS.
In a cohort of 1510 patients receiving treatment for
MS in the US, adherence to DMDs was shown to be as-
sociated with significantly lower healthcare resource
utilization [34]. However, this analysis did not include an
evaluation of the degree of disability for these patients.
Our research has shown that, increased disability and
current relapse were both associated with an increase in
health care resource utilization. This was reflected in the
increased numbers of health care practitioner visits, not-
ably to neurologists, MS nurses and physiotherapist. The
likelihood of requiring at least one hospitalization in the
previous 12 months was also significantly increased for
the most disabled patients compared with those in the
least disabled category. Of particular note was the obser-
vation that as disability increased, the likelihood of need-
ing to visit the ER increased. Indeed, for patients with an
EDSS score >5 the number of ER visits was 15 times
higher than that for patients with an EDSS score <3. Re-
cently, Oynhausen et al. examined the acute care needs
of patients with MS presenting to the Mount Sinai ER
[35]. They found that patients with MS were most likely
to present in the ER with non-neurological problems
such as urinary tract infections.
Perhaps unsurprisingly given the pervasive nature of
the impact of MS on all aspects of the daily lives of pa-
tients with MS, increased disability was associated with
an increased likelihood of reduced HRQoL. A previous
study among patients with MS covering the period 1998
to 2009 demonstrated the negative impact of MS on
HRQoL and reported that patients with MS lost 10.4
quality-adjusted life years as a consequence of their dis-
ease compared to individuals without MS [3]. Among
patients with the relapsing-remitting MS, physical symp-
toms such as pain, stiffness and muscle spasms were re-
lated to physical QoL [36]. The presence of depression
and cognitive impairments were more closely associated
with work impairments. Our results confirm these find-
ings and highlight the association between disability and
HRQoL in MS patients. The specific drivers of HRQoL
decrements in MS are not well defined. A recent study
among 97 patients identified increased EDSS score and
the presence of depressive symptomatology as relevant
determinant of QoL among patients with MS [37]. Con-
sistent with this, a larger study in a cohort of 949 adults
with MS in Canada found that increased disability, de-
pression and anxiety, fatigue and physical comorbidity
were all associated with decreased HRQoL [38]. To-
gether, these studies support the importance of targeting
disability in order to achieve improved HRQoL for
patients.
In addition to detrimental effects of increased disabil-
ity on work capacity and productivity, our results also
demonstrated an association between increaseddisability
and the ability of patients to undertake activities of daily
living. As MS-related disability increased, the likelihood
of patients to be able to successfully self-care and
complete usual household tasks reduced, and the need
for informal care and support increased. An increase in
disability was associated with an increased likelihood of
requirement assistance with a range of usual self-care
activities from getting out of bed to preparing meals and
travelling outside the home. This may be because the
EDSS was used to describe disability in the current re-
search, a tool that focuses mainly on functional capabil-
ities, specifically walking ability, to determine disability.
A previous study showed that cognitive aspects of the
disease, such as the ability of the patient to make deci-
sions about daily tasks, were associated with caregiver
employment [39]. A systematic evaluation of the impact
of the symptom profile of patients with MS on caregiver
burden is lacking and may inform the holistic support
patients with MS and their informal caregivers require.
The burden of and costs associated with MS have been
investigated using many different models including
cross-sectional studies, retrospective analyses, patient
self-completion questionnaires and data obtained from
healthcare claims databases. Such studies have shown
the costs associated with MS disability to be consider-
able for individuals, their families and for society as a
whole [3, 18, 40, 41]. Initiation of DMDs early in the
Table 6 Relationship between disability (EDSS) and relapse and direct health care costs over the previous 12 months among
patients with MS
Parameter, (95 % CI) a Disability (reference group EDSS <3) Relapse (reference
group no relapse)
R2, %
EDSS 3–5 EDSS >5
Costs of consultations in last 12 months (US$) 692* (242.6–1141.3) 730* (358.1–1101.4) 464* (232.4–695.9) 16.53
Cost of hospitalisations in last 12 months (US$) 3,007 (−363.4–6377.6) 10,883* (4025.6–17739.8) 3,693* (1313.9–6072.3) 10.84
Cost of current treatment regimen in last 12 months (US$) 318 (−2129.6–2765.6) 1,711 (−1466.3–4888.3) 233 (−1704.6–2170.2) 1.55
Total costs (US$) 4,017 (−916.5–8950.7) 13,324* (4872.1–21774.8) 4,390* (1248.3–7531.8) 8.75
EDSS Expanded Disability Status Scale, MS multiple sclerosis
*p < 0.05
aOrdinary least squares regression analysis to yield coefficients and 95 % CIs (covariates: patient age, sex and body mass index)
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disease course has been shown to slow the neurodegen-
erative changes that may underpin physical disability
and to reduce relapse frequency [42]. Our research has
demonstrated that such a strategy could offer consider-
able benefits both in terms of the associated cost burden
and the personal burden to patients, allowing patients to
continue to work, care for themselves and their families.
Our research has demonstrated the association between
disability and relapses and direct medical costs; specific-
ally, elevated health care professional consultations, and,
increased hospitalization costs for those with the highest
levels of disability.
When considering the results presented here, it is im-
portant to acknowledge the limitations of the design of
this research. Cross-sectional analyses such as presented
here are hypothesis-generating in that they allow identi-
fication of associations (rather than causal relationships)
between variable factors and the outcomes of interest.
Data were derived by a survey-based methodology with
physicians providing data available at the time of con-
sultation. The pragmatic approach to accruing the pa-
tient sample, while practical in terms of deriving a large
patient population, may have excluded relevant types of
patients including those not currently receiving treat-
ment or those not currently requiring physician consult-
ation. Our patient cohort consisted of predominantly
Caucasian, female patients consistent with the epi-
demiology of MS. Despite this, our cohort may not
be entirely representative of the US MS patient popu-
lation and, as it consisted of only patients consulting
their physician at the time the research was con-
ducted. Although pragmatic, this approach may have
limited the generalizability of our observations to the
entire MS population in the US. An additional limita-
tion of this research that must be acknowledged is
the lack of nationally representative cost data for the
US. Actual patient-level cost data is determined by
the healthcare plan to which the patient belongs. As
it was beyond the scope of the current research to
collect actual patient-level cost data, alternative unit
costs sources were utilized. Where possible, official
cost data from national social insurance programmes
administered by the US federal government were uti-
lized as these were regarded as the most reliable and
nationally representative sources. A disadvantage of
these sources is that they provide average costs
regardless of patient-level diagnosis and so may not
necessarily represent the actual costs of care for pa-
tients with MS. Despite these limitations, the aim of
the research was to evaluate the impact of disease
progression as reflected by increased disability mea-
sured using the EDSS, as such our patient cohort was
stratified by EDSS score, with a score <3 group pro-
viding an internal control for comparisons.
Conclusions
In summary, our research has shown that the burden
and cost of MS increases with progression of disability
as measured by the EDSS and with current relapse. Our
research highlights the need for treatments targeted at
slowing down or improving the physical disabilities asso-
ciated with MS to improve patient work capacity,
HRQoL, and patient ability to self-care as well as to
mitigate increased health resource utilization and its as-
sociated costs.
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